Email Updates

Search form

You are here

HIV Vaccine

There is momentum and promise in the search for an HIV vaccine.

An effective preventive HIV vaccine would teach the body how to prevent HIV infection. Vaccines are the most powerful public health tools available—and an HIV vaccine would play a powerful role in ensuring the end to the AIDS epidemic.

While effective vaccines remain years away, there are more reasons for hope than ever before. Researchers are expanding on the result of a 2009 trial that showed, for the first time, that a vaccine can reduce the risk of HIV infection. They’re also pursuing groundbreaking research with other novel vaccine strategies, including broadly neutralizing antibodies that target a wide range of HIV strains. At the same time, there is also exciting work in efforts to understand if and how to cure HIV in people who are already infected. The timeline for this work is long and uncertain. Here, too, advocacy is needed to sustain momentum.

Today’s momentum depends on sustained funding. Policy makers and funders around the world must have the courage to sustain vital HIV vaccine research for years to come, and advocates must keep the pressure on them to maintain their commitments.

What We're Reading

Nature reports on the push from advocates to invest early in a plan to deliver a vaccine, or other prevention interventions, even while trials are still underway. The article is pegged to a World Health Organization convening in late February and early March to discuss how to deliver new interventions more swiftly after trial results show a success.

February 27, 2018
Antibody Related Research, HIV Vaccine
Nature

Technical advances in vaccine production should shorten the time to clinical trials, breaking the logjam of promising new candidate vaccines waiting to be tested.

February 9, 2018
Science Daily

The Vaccine Advocacy Resource Group (VARG) and South African Medical Research Council (SA MRC) jointly convened a meeting of African advocates to discuss the standard of prevention and care in HIV prevention trials. Based on the meeting discussions, the VARG presented this advocates’ statement at the follow-up MRC summit, convened to inform policy discussions about the standard of care, including oral PrEP, at trial sites in South and Southern Africa. Download the full statement and read additional context around the recent convenings on this important issue.

November 3, 2017
Vaccine Advocacy Resource Group (VARG)
Subscribe to RSS - HIV Vaccine